Pfizer announced changes to its executive leadership team. Chris Boshoff will join Pfizer’s Executive Leadership Team as Chief Oncology Research and Development Officer and Executive Vice President reporting to Chairman and CEO Albert Bourla. Boshoff will be the single point of accountability for the entire oncology pipeline. Previously, Boshoff oversaw clinical research and product development activities for Pfizer’s Oncology portfolio. Before assuming leadership roles in the biopharmaceutical industry, Boshoff served as Director of the University College London Cancer Institute. In addition to his expanded role, Dr Boshoff is leading the integration planning for Seagen’s medicines and team. Mikael Dolsten, currently Chief Scientific Officer & President, Pfizer Worldwide Research, Development and Medical, will now expand his role to lead all discovery, early- and late-stage clinical development, for all non-oncology therapeutic areas as Chief Scientific Officer, President, Pfizer Research & Development. As a result of these moves, William Pao, Chief Development Officer, and Executive VP will be leaving Pfizer in the month ahead to pursue new opportunities outside the company.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PFE:
- GSK announces ViiV’s cabotegravir for HIV prevention gets positive CHMP opinion
- Ex-Dividend Date Nearing for These 10 Stocks – Week of July 24, 2023
- FDA doesn’t see immediate significant impacts on supply from Pfizer plant damage
- Pfizer announces post-tornado relief plans for Rocky Mount facility
- Pfizer announces positive CHMP opinion for RSV vaccine candidate